Biotek-snakken — August 2022
-
@Bioshare, den er ikke så lille længere, holder stadig, købte flere da den gik under 10. Sålænge scripts stiger holder jeg. Super possitivt med godkendelse i Endo, skal nok også blive godkendt i EU. Desvære ikke mange retail investors i den, så det bliver nok det lange seje træk inden vi skal i ny ATH. De proffesionelle har jo købt.
-
@Sukkeralf, har du set, at Zyme bruger site-specific conjugation for deres nye ADC platform? Det havde jeg i hvert fald ikke. https://ir.zymeworks.com/static-files/efbb3a4f-99d3-4eb2-9c9f-681abd2e1b6c side 5
-
altimmune rykker. Business update fra Q2 f
inancial results ser lovende ud: https://www.biopharmcatalyst.com/company/ALT/news/89603 -
2 Tips for Investing in Biotech Stocks With High Growth Potential https://www.proinvestor.com/investornyt/866528/2-tips-for-investing-in-biotech-stocks-with-high-growth-potential
-
Som tidligere nævnt går de efter et selskab der vil udvikle RPT93 bredt og serielt, for ellers ønsker de at tage AD og astma indikationerne længere frem, før de laver en aftale. Deres CEO Brian Wong sagde tidligere, at baren var høj hvis de skulle have nogen ind nu.
-
bluebird bio Announces FDA Approval of ZYNTEGLO
, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-fda-approval-zynteglor-first-gene-therapy
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind